研究单位：[1]Chengdu Kanghong Biotech Co., Ltd.[2]Beijing Friendship Hospital,Capital Medical University,Beijing,China[3]Beijing Tongren Hospital, Capital Medical University,Beijing,China[4]Peking Union Medical College Hospital,Beijing,China[5]Peking University First Hospital,Beijing,China[6]Peking University People's Hospital,Beijing,China[7]Peking University Third Hospital,Beijing,China[8]The General Hospital of the People's Liberation Army,Beijing,China[9]The Second Hospital of Jilin University,Changchun,China[10]The Second Xiangya Hospital of Central South University,Changsha,China[11]West China Hospital Sichuan University,Chengdu,China[12]Army Medical Center,Chongqing,China[13]The Second Hospital of Dalian Medical University,Dalian,China[14]Zhongshan Ophthalmic Center,Guangzhou,China[15]The 2nd Affiliated Hospital of Harbin Medical University,Harbin,China[16]The Jiangxi Provincial People's Hospital,Nanchang,China[17]Nanjing First Hospital,Nanjing,China[18]The First Affiliated Hospital of Guangxi Medical University,Nanning,China[19]Eye & Ent Hospital of Fudan University,Shanghai,China[20]Shanghai General Hospital,Shanghai,China[21]Zhongshan Hospital,Shanghai,China[22]The First Hospital of China Medical University,Shenyang,China[23]Tianjin Eye Hospital,Tianjin,China[24]Tianjin Medical University Eye Hospital School of Optometry & Eye Institute,Tianjin,China[25]The First Affiliated Hospital of Xinjiang Medical University,Urumqi,China[26]Eye Hospital,WMU Zhejiang Eye Hospital,Wenzhou,China[27]Wuhan General Hospital of Guangzhou Military Command,Wuhan,China[28]The First Affiliated Hospital of Xi'An Jiaotong University,Xi'an,China
This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study. 237 patients with central retinal vein occlusion(CRVO) are expected to be enrolled in the study and randomly assigned into the Conbercept ophthalmic injection treatment group or the control group at a ratio of 2:1.
